Cogent Biosciences, Inc.
Income Statement
| Line Item | FY2018 | FY2017 |
|---|---|---|
| Revenue | $9.7M | $8.4M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $38.3M | $29.8M |
| SG&A Expense | $7.5M | $4.7M |
| Operating Income | $-36.0M | $-26.2M |
| Operating Margin | -369.9% | -312.8% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-34.5M | $-25.5M |
| Net Margin | -354.8% | -304.9% |
| EPS (Basic) | $-1.39 | $-2.51 |
| EPS (Diluted) | $-1.39 | $-2.51 |
| Shares Outstanding (Basic) | 30.1M | 10.2M |
| Shares Outstanding (Diluted) | 30.1M | 10.2M |
| Dividends Per Share | — | — |